Low Molecular Weight Heparin in Recurrent Implantation Failure
Empirical Low Molecular Weight Heparin Administration in the Luteal Phase in Patients With Recurrent Implantation Failures: a Randomized Open Labeled Trial
Lead SponsorV.K.V. American Hospital, Istanbul
StatusCompleted No Results Posted
Indication/ConditionFertilization in Vitro Recurrent Implantation Failure Infertility
Intervention/Treatmentprogesterone enoxaparin ...
Recurrent implantation failure is the failure to achieve a pregnancy after multiple attempts with in vitro fertilization treatment. The reason is usually obscure. Many empirical treatments have been offered without substantial evaluation. Heparin is thought to play a role in the embryo implantation process beyond its anticoagulation effects. The proposed study aims to assess the effectiveness and safety of empirical administration of low molecular weight heparin in patients undergoing a new IVF treatment cycle after multiple failed attempts.
1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
routine luteal phase support with progesterone gel
Women in the LMWH arm are administered 1 mg/kg/day subcutaneously low molecular weight heparin after oocyte collection in addition to routine luteal phase support with vaginal progesterone
Women in the control arm are administered routine luteal phase support without the addition of LMWH
Inclusion Criteria: History of at least two previously failed fresh embryo transfer cycles All previously failed cycles to be performed in the American Hospital of Istanbul Female age ≤ 38 years Fresh ejaculate sperms to be used for ICSI No hormonal, coagulation, or immunological disorders detected Normal uterine cavity, as assessed by diagnostic office hysteroscopy or saline infusion sonography Normal female and male peripheral karyotype